Health-related quality of life in long-term survivors with localised prostate cancer by therapy

• Verfasst von: Adam, Salome [VerfasserIn]
• Verfasst von: Brenner, Hermann [VerfasserIn]
• Verfasst von: Arndt, Volker [VerfasserIn]
• Titel: Health-related quality of life in long-term survivors with localised prostate cancer by therapy
• Titelzusatz: results from a population-based study
• Verf.angabe: Salome Adam, Lena Koch‐Gallenkamp, Heike Bertram, Andrea Eberle, Bernd Holleczek, Ron Pritzkuleit, Mechthild Waldeyer‐Sauerland, Annika Waldmann, Sylke Ruth Zeissig, Sabine Rohrmann, Hermann Brenner, Volker Arndt
• E-Jahr: 2019
• Jahr: 02 May 2019
• Umfang: 10 S.
• Teil: volume:28
• Teil: year:2019
• Teil: number:5
• Teil: extent:10
• Fussnoten: Gesehen am 21.10.2019
• Titel Quelle: Enthalten in: European journal of cancer care
• Ort Quelle: Oxford [u.a.] : Wiley-Blackwell, 1992
• Jahr Quelle: 2019
• Band/Heft Quelle: 28(2019,5) Artikel-Nummer e13076, 10 Seiten
• ISSN Quelle: 1365-2354
• DOI: doi:10.1111/ecc.13076
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: health-related quality of life
• Sach-SW: prostate cancer
• Sach-SW: therapy
• Sach-SW: well-being
• K10plus-PPN: 1679254367

Abstract

Objective: Several therapies for localised prostate cancer (PC) are available; all yield similar survival rates. However, each therapy has significant side effects that can influence patients' health-related quality of life (HRQoL) in the long run. Methods: The study sample included 911 survivors with localised PC, 5-15 years post-diagnosis who were identified from the population-based CAESAR + study in Germany. HRQoL was assessed using the EORTC QLQ-C30 and EORTC QLQ-PR25 questionnaires. The association between type of therapy and HRQoL was assessed with multivariable linear regression and global F-test adjusting for age, time since diagnosis and comorbidities. Results: Overall, survivors treated with radical prostatectomy (RP) or radiotherapy (RT) alone reported the best HRQoL and the lowest symptom burden. Conversely, survivors treated with androgen deprivation therapy (ADT) (& RP/RT) or RP & RT (in combination) reported the worst HRQoL and the highest symptom burden. Significant differences among treatment groups in HRQoL were found for global health status (p = 0.041), social functioning (p = 0.007), urinary symptoms (p = 0.035), bowel symptoms (p = 0.017) and hormonal treatment-related symptoms (p < 0.001) among other symptoms. Conclusions: Long-term localised PC survivors formerly treated with a combination of RP and RT or with ADT report poorer HRQoL and more symptoms than patients treated with either RP or RT alone.